Novavax Expands Matrix-M Adjuvant Deals Through Partnership With Sanofi
Novavax, Inc. of Gaithersburg, Maryland is continuing to move away from relying primarily on direct vaccine sales and is instead focusing more heavily on licensing agreements and corporate partnerships. The company recently expanded deals with pharmaceutical giants Pfizer, Inc. and Sanofi SA as it attempts to build a more stable revenue stream following a sharp […]
Novavax Signs Licensing Agreement With Pfizer for Vaccine Adjuvant Technology
Novavax, Inc. and Pfizer, Inc. have signed a licensing arrangement allowing Pfizer access to Novavax’s Matrix-M adjuvant technology to boost immune response to vaccines. The agreement will allow for use in vaccines targeting up to two infectious diseases.1 Novavax’s Matrix-M technology is an aluminum-free adjuvant designed to enhance the immune response in protein-based vaccines such […]
FDA Approves Novavax’s COVID-19 Vaccine With Restrictions
On May 16, 2025, the U.S. Food and Drug Administration (FDA) approved licensure of Novavax, Inc.’s Nuvaxovid protein-based COVID-19 vaccine, which has been available in the United States under Emergency Use Authorization (EUA) since July 2022.1 The decision for a full licensure was postponed while the new agency leadership under the current administration conducted a […]